Overview

Study of Darbepoetin Alfa for the Treatment of Anemia of Cancer

Status:
Completed
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy of darbepoetin alfa versus placebo in reducing the occurrences of red blood cell transfusions in subjects with anemia of cancer who are not receiving chemotherapy.
Phase:
Phase 3
Details
Lead Sponsor:
Amgen
Treatments:
Darbepoetin alfa